Denali Historical Financial Ratios
| DNLI Stock | USD 25.00 0.16 0.64% |
Denali Therapeutics is recently reporting on over 94 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 2.17 or Days Sales Outstanding of 3.59 will help investors to properly organize and evaluate Denali Therapeutics financial condition quickly.
Denali |
About Denali Financial Ratios Analysis
Denali TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Denali Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Denali financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Denali Therapeutics history.
Denali Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Denali Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Denali Therapeutics sales, a figure that is much harder to manipulate than other Denali Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is Denali Therapeutics dividend as a percentage of Denali Therapeutics stock price. Denali Therapeutics dividend yield is a measure of Denali Therapeutics stock productivity, which can be interpreted as interest rate earned on an Denali Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Denali Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.As of now, Denali Therapeutics' Income Quality is increasing as compared to previous years. The Denali Therapeutics' current Current Ratio is estimated to increase to 15.07, while Price To Sales Ratio is projected to decrease to 8.47.
| 2022 | 2023 | 2024 (projected) | Graham Number | 22.03 | 13.36 | 12.69 | Receivables Turnover | 11.69 | 96.65 | 101.48 |
Denali Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Denali Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Denali Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 62.43 | 27.19 | 111.38 | 32.19 | 8.92 | 8.47 | |
| Ptb Ratio | 4.22 | 7.93 | 5.63 | 3.35 | 2.86 | 2.17 | |
| Book Value Per Share | 4.13 | 10.56 | 7.92 | 8.3 | 7.5 | 13.43 | |
| Free Cash Flow Yield | 0.0244 | (0.1) | 0.0453 | (0.0406) | (0.0752) | (0.13) | |
| Operating Cash Flow Per Share | (1.59) | 3.82 | (1.74) | (1.95) | (2.61) | (2.74) | |
| Capex To Depreciation | 2.24 | 0.36 | 0.99 | 1.72 | 0.77 | 0.73 | |
| Pb Ratio | 4.22 | 7.93 | 5.63 | 3.35 | 2.86 | 2.17 | |
| Ev To Sales | 62.03 | 25.87 | 106.56 | 30.73 | 8.69 | 8.26 | |
| Free Cash Flow Per Share | (1.77) | 3.79 | (1.81) | (2.09) | (2.7) | (2.84) | |
| Roic | (0.11) | (0.54) | 0.0539 | (0.31) | (0.33) | (0.2) | |
| Net Income Per Share | (2.07) | 0.65 | (2.39) | (2.6) | (1.06) | (1.11) | |
| Payables Turnover | 74.66 | 198.52 | 1.17 | 2.52 | 1.76 | 1.68 | |
| Sales General And Administrative To Revenue | 1.74 | 0.18 | 1.62 | 0.83 | 0.31 | 0.3 | |
| Research And Ddevelopement To Revenue | 7.25 | 0.63 | 5.45 | 3.31 | 1.28 | 1.22 | |
| Capex To Revenue | 0.67 | 0.009221 | 0.17 | 0.16 | 0.0391 | 0.0372 | |
| Cash Per Share | 4.34 | 13.49 | 7.12 | 10.64 | 7.53 | 13.85 | |
| Pocfratio | (10.99) | 21.93 | (25.64) | (14.27) | (8.23) | (7.82) | |
| Capex To Operating Cash Flow | (0.12) | 0.007437 | (0.0402) | (0.0729) | (0.0361) | (0.038) | |
| Pfcf Ratio | (9.83) | 22.1 | (24.65) | (13.3) | (7.95) | (7.55) | |
| Days Payables Outstanding | 4.89 | 1.84 | 310.99 | 144.82 | 206.94 | 196.59 | |
| Income Quality | 0.77 | 5.85 | 0.73 | 0.75 | 2.47 | 2.59 | |
| Roe | (0.5) | 0.0618 | (0.3) | (0.31) | (0.14) | (0.15) | |
| Ev To Operating Cash Flow | (10.92) | 20.87 | (24.53) | (13.62) | (8.03) | (7.62) | |
| Pe Ratio | (8.43) | 128.31 | (18.65) | (10.71) | (20.3) | (19.28) | |
| Return On Tangible Assets | (0.0547) | (0.36) | 0.0443 | (0.21) | (0.22) | (0.13) | |
| Ev To Free Cash Flow | (9.76) | 21.03 | (23.58) | (12.7) | (7.75) | (7.36) | |
| Earnings Yield | (0.12) | 0.007793 | (0.0536) | (0.0934) | (0.0493) | (0.0517) | |
| Net Debt To E B I T D A | 0.0516 | (7.06) | 0.82 | 0.48 | 0.42 | 0.21 | |
| Current Ratio | 9.48 | 20.86 | 2.37 | 3.77 | 13.65 | 15.07 | |
| Tangible Book Value Per Share | 4.13 | 10.56 | 7.92 | 8.3 | 7.5 | 13.43 | |
| Graham Number | 13.86 | 12.45 | 20.64 | 22.03 | 13.36 | 12.69 | |
| Shareholders Equity Per Share | 4.13 | 10.56 | 7.92 | 8.3 | 7.5 | 13.43 | |
| Graham Net Net | 2.69 | 9.32 | 3.49 | 7.35 | 6.65 | 9.43 |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.